Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1919 1
1967 1
1969 3
1971 2
1972 3
1973 1
1974 2
1975 7
1976 6
1977 2
1978 3
1979 9
1980 5
1981 3
1982 4
1983 5
1984 5
1985 3
1986 3
1987 6
1988 10
1989 9
1990 3
1991 12
1992 3
1993 7
1994 13
1995 14
1996 6
1997 11
1998 20
1999 11
2000 23
2001 23
2002 19
2003 12
2004 26
2005 25
2006 27
2007 30
2008 23
2009 17
2010 17
2011 15
2012 24
2013 25
2014 42
2015 33
2016 46
2017 40
2018 45
2019 39
2020 46
2021 51
2022 55
2023 51
2024 21

Text availability

Article attribute

Article type

Publication date

Search Results

888 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: Chung-Khain
Page 1
The anti-ovarian cancer activity by WYE-132, a mTORC1/2 dual inhibitor.
Zhang D, Xia H, Zhang W, Fang B. Zhang D, et al. Tumour Biol. 2016 Jan;37(1):1327-36. doi: 10.1007/s13277-015-3922-0. Epub 2015 Aug 21. Tumour Biol. 2016. PMID: 26293898
Meanwhile, WYE-132 induced caspase-dependent apoptosis in ovarian cancer cells. ...These results demonstrate that WYE-132 inhibits ovarian cancer cell proliferation through mTOR-dependent and mTOR-independent mechanisms and indicate a potential value of WYE-1 …
Meanwhile, WYE-132 induced caspase-dependent apoptosis in ovarian cancer cells. ...These results demonstrate that WYE-132 inhi …
Rapamycin and WYE-354 suppress human gallbladder cancer xenografts in mice.
Weber H, Leal P, Stein S, Kunkel H, García P, Bizama C, Espinoza JA, Riquelme I, Nervi B, Araya JC, Grez M, Roa JC. Weber H, et al. Oncotarget. 2015 Oct 13;6(31):31877-88. doi: 10.18632/oncotarget.5047. Oncotarget. 2015. PMID: 26397134 Free PMC article.
We evaluated the in vitro and in vivo antitumor efficacy of mTOR inhibitors, rapamycin and WYE-354. In vitro assays showed WYE-354 significantly reduced cell viability, migration and invasion and phospho-P70S6K expression in GBC cells. Mice harboring subcutaneous ga …
We evaluated the in vitro and in vivo antitumor efficacy of mTOR inhibitors, rapamycin and WYE-354. In vitro assays showed WYE …
Assessment of [125I]WYE-230949 as a novel histamine H3 receptor radiopharmaceutical.
Lewis DY, Champion S, Wyper D, Dewar D, Pimlott S. Lewis DY, et al. PLoS One. 2014 Dec 26;9(12):e115876. doi: 10.1371/journal.pone.0115876. eCollection 2014. PLoS One. 2014. PMID: 25542008 Free PMC article.
Histamine H3 receptor therapeutics have been proposed for several diseases such as schizophrenia, attention deficit hyperactivity disorder, Alzheimer's disease and obesity. We set out to evaluate the novel compound, [125I]WYE-230949, as a potential radionuclide imaging age …
Histamine H3 receptor therapeutics have been proposed for several diseases such as schizophrenia, attention deficit hyperactivity disorder, …
WYE-354 restores Adriamycin sensitivity in multidrug-resistant acute myeloid leukemia cell lines.
Ibrahim SM, Bakhashab S, Ilyas AM, Pushparaj PN, Karim S, Khan JA, Abuzenadah AM, Chaudhary AG, Al-Qahtani MH, Ahmed F. Ibrahim SM, et al. Oncol Rep. 2019 Jun;41(6):3179-3188. doi: 10.3892/or.2019.7093. Epub 2019 Apr 2. Oncol Rep. 2019. PMID: 30942458 Free PMC article.
Furthermore, WYE-354 stimulated the ATPase activity of ABCB1, which was consistent with in silico predictions using a human ABCB1 mouse homology model, indicating that WYE-354 is a potent substrate of ABCB1. WYE-354 did not regulate the expression of ABCB1 at …
Furthermore, WYE-354 stimulated the ATPase activity of ABCB1, which was consistent with in silico predictions using a human ABCB1 mou …
Autophagy inhibition sensitizes WYE-354-induced anti-colon cancer activity in vitro and in vivo.
Wang L, Zhu YR, Wang S, Zhao S. Wang L, et al. Tumour Biol. 2016 Sep;37(9):11743-11752. doi: 10.1007/s13277-016-5018-x. Epub 2016 Mar 28. Tumour Biol. 2016. PMID: 27020593
In addition, WYE-354 treatment activated caspase-dependent apoptosis in the colon cancer cells. ...Phosphorylations of Akt (Ser-473) and S6 were also decreased in WYE-354-treated HT-29 xenografts. Together, these pre-clinical results demonstrate the potent anti-colo …
In addition, WYE-354 treatment activated caspase-dependent apoptosis in the colon cancer cells. ...Phosphorylations of Akt (Ser-473) …
Impact of regional analgesia in surgery.
Yeung J, Small C. Yeung J, et al. Br J Surg. 2021 Sep 27;108(9):1009-1010. doi: 10.1093/bjs/znab214. Br J Surg. 2021. PMID: 34131701 Free PMC article. Review. No abstract available.
Preclinical evaluation of WYE-687, a mTOR kinase inhibitor, as a potential anti-acute myeloid leukemia agent.
Cheng F, Wang L, Shen Y, Xia J, Chen H, Jiang Y, Lu M. Cheng F, et al. Biochem Biophys Res Commun. 2016 Feb 5;470(2):324-330. doi: 10.1016/j.bbrc.2016.01.054. Epub 2016 Jan 11. Biochem Biophys Res Commun. 2016. PMID: 26792718
Here, we investigated the potential anti-leukemic activity by WYE-687, a potent mTOR kinase inhibitor. We demonstrated that WYE-687 potently inhibited survival and proliferation of established (HL-60, U937, AML-193 and THP-1 lines) and human AML progenitor cells. .. …
Here, we investigated the potential anti-leukemic activity by WYE-687, a potent mTOR kinase inhibitor. We demonstrated that WYE …
Ill feelings.
Dawnay G. Dawnay G. Br J Gen Pract. 2020 May 28;70(695):299. doi: 10.3399/bjgp20X710261. Print 2020 Jun. Br J Gen Pract. 2020. PMID: 32467212 Free PMC article. No abstract available.
Overexpression of ABCB1 Transporter Confers Resistance to mTOR Inhibitor WYE-354 in Cancer Cells.
Wang J, Yang DH, Yang Y, Wang JQ, Cai CY, Lei ZN, Teng QX, Wu ZX, Zhao L, Chen ZS. Wang J, et al. Int J Mol Sci. 2020 Feb 19;21(4):1387. doi: 10.3390/ijms21041387. Int J Mol Sci. 2020. PMID: 32092870 Free PMC article.
We demonstrated that WYE-354 is a substrate of ABCB1, that the overexpression of the ABCB1 transporter decreases the efficacy of WYE-354, and that the resistant WYE-354 can be reversed by an ABCB1 inhibitor at a pharmacological achievable concentration. ...In …
We demonstrated that WYE-354 is a substrate of ABCB1, that the overexpression of the ABCB1 transporter decreases the efficacy of W …
888 results